Literature DB >> 14962851

Thalassaemia major: the murky story of deferiprone.

Julian Savulescu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14962851      PMCID： PMC341373          DOI： 10.1136/bmj.328.7436.358

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  10 in total

1.  The hexamethonium asthma study and the death of a normal volunteer in research.

Authors:  J Savulescu; M Spriggs
Journal:  J Med Ethics       Date:  2002-02       Impact factor: 2.903

2.  Two deaths and two lessons: is it time to review the structure and function of research ethics committees?

Authors:  J Savulescu
Journal:  J Med Ethics       Date:  2002-02       Impact factor: 2.903

3.  Trials sponsored by drug companies: review ordered.

Authors:  David Spurgeon
Journal:  BMJ       Date:  1998-09-05

4.  Deferiprone and hepatic fibrosis.

Authors:  Gary M Brittenham; David G Nathan; Nancy F Olivieri; John B Porter; Martin Pippard; Elliott P Vichinsky; David J Weatherall
Journal:  Blood       Date:  2003-06-15       Impact factor: 22.113

5.  Introduction to The Olivieri symposium.

Authors:  A M Viens; J Savulescu
Journal:  J Med Ethics       Date:  2004-02       Impact factor: 2.903

6.  Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia.

Authors:  Lisa J Anderson; Beatrix Wonke; Emma Prescott; Sally Holden; J Malcolm Walker; Dudley J Pennell
Journal:  Lancet       Date:  2002-08-17       Impact factor: 79.321

7.  Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia.

Authors:  Ian R Wanless; George Sweeney; Amar P Dhillon; Maria Guido; Antonio Piga; Renzo Galanello; M Rita Gamberini; Elias Schwartz; Alan R Cohen
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

8.  Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.

Authors:  N F Olivieri; G M Brittenham; C E McLaren; D M Templeton; R G Cameron; R A McClelland; A D Burt; K A Fleming
Journal:  N Engl J Med       Date:  1998-08-13       Impact factor: 91.245

9.  Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis.

Authors:  Antoni Piga; Carmen Gaglioti; Eugenia Fogliacco; Fernando Tricta
Journal:  Haematologica       Date:  2003-05       Impact factor: 9.941

10.  Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.

Authors:  Alan R Cohen; Renzo Galanello; Antonio Piga; Vincenzo De Sanctis; Fernando Tricta
Journal:  Blood       Date:  2003-05-22       Impact factor: 22.113
  10 in total
  5 in total

1.  Take Two Iron Chelators and Call Me in the Morning.

Authors:  Steven J Fliesler
Journal:  Transl Vis Sci Technol       Date:  2012-10-25       Impact factor: 3.283

2.  New developments and controversies in iron metabolism and iron chelation therapy.

Authors:  Christina N Kontoghiorghe; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2016-03-26

Review 3.  World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

Authors:  Christina N Kontoghiorghe; Nicholas Andreou; Katerina Constantinou; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2014-09-26

4.  Intermicrobial interaction: Aspergillus fumigatus siderophores protect against competition by Pseudomonas aeruginosa.

Authors:  Gabriele Sass; Shajia R Ansari; Anna-Maria Dietl; Eric Déziel; Hubertus Haas; David A Stevens
Journal:  PLoS One       Date:  2019-05-08       Impact factor: 3.752

Review 5.  The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia.

Authors:  George J Kontoghiorghes; Marios Kleanthous; Christina N Kontoghiorghe
Journal:  Mediterr J Hematol Infect Dis       Date:  2020-01-01       Impact factor: 2.576
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.